GlassScriptPhysician profile
Amanda T Sullivan
NPI 1386010379
$5,202.00
in general payments reported to CMS, 2019-2025
33 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,453 · 2022: $1,244 · 2023: $1,247 · 2024: $621 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.96 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.71 | 2021-2025 | |
| Exeltis, USA INC. | $954.95 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $424.33 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $326.22 | 2021-2025 | |
| Organon LLC | $320.38 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $306.07 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $296.76 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $193.09 | 2021-2025 | Wegovy, Saxenda |
| Hologic Sales and Service, LLC | $146.17 | 2023-2025 | Novasure, Myosure Tissue Removal Device |
| Myriad Women'S Health, INC. | $132.07 | 2023 | Myrisk |
| Biohaven Pharmaceutical Holding Company LTD. | $109.16 | 2022 | |
| Daiichi Sankyo INC. | $104.89 | 2021-2022 | |
| Shield Therapeutics INC | $102.66 | 2022-2025 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $102.45 | 2021 | |
| Evofem Biosciences, INC. | $77.05 | 2021-2025 | Solosec, Phexx, Phexxi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $68.27 | 2021 | |
| Sumitomo Pharma America, INC. | $59.12 | 2024-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $52.00 | 2022-2025 | |
| Lilly USA, LLC | $41.70 | 2021-2025 | Zepbound |
| Urovant Sciences INC | $41.52 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $32.55 | 2021-2024 | Onzetra Xsail, Contrave |
| Davol INC. | $27.90 | 2024 | Arista Ah Flexitip |
| Myovant Sciences INC. | $25.18 | 2022 | |
| Solventum Corporation | $24.80 | 2025 | Prevena |
| Merck Sharp & Dohme LLC | $23.26 | 2021 | |
| Becton, Dickinson and Company | $18.37 | 2022 | |
| Dexcom, INC. | $17.63 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $17.25 | 2021 | |
| Minerva Surgical, INC | $17.24 | 2024 | |
| Avion Pharmaceuticals | $16.92 | 2023 | Balcoltra |
| Radius Health, INC. | $14.22 | 2021 | |
| Smith+Nephew, INC. | $12.10 | 2022 | |
| Allegis Pharmaceuticals, LLC | $11.01 | 2023 | Urimar-T Caps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.